About: Board of Directors

Brian A. Pollok, Ph.D. – CEO

Dr. Pollok has over 20 years career experience in the pharmaceutical and biotechnology industry, serving as a Sr. Investigator for Pfizer, Vice President of Discovery Biology at Aurora Biosciences/Vertex Pharmaceuticals, Sr. VP of R&D at Ansata Therapeutics, VP of R&D at Invitrogen, Chief Scientific Officer of Life Technologies, and most recently as President of ATCC.

Dr. Pollok’s background is as a science/business hybrid, bringing current scientific knowledge together with business experience and acumen. Included in his career accomplishments are: (1) the discovery of the first NME specifically designed to treat spinal muscular atrophy (RG-3039, currently in clinical development by Pfizer) and its unique molecular target, (2) invention of Z’-Lyte™ assay technology which has generated over $65M in revenues to date and enabled lead optimization of several clinically effective kinase inhibitors such as vemurafenib (an FDA-approved drug for malignant melanoma), and (3) building two high-growth, innovation-driven organizations (Aurora and Invitrogen-Madison).

John Herr, Ph.D. – Scientific Founder

Dr. Herr is the scientific leader for Neoantigenics, chairing the Scientific Advisory Council. Dr. Herr is Professor of Cell Biology, Urology, and Biomedical Engineering at the University of Virginia Medical School, where he is a member of the Cancer Center and serves as Faculty Director of the Lymphocyte Culture Center, which he founded in 1982.

Dr. Herr also founded the Center for Research in Contraceptive and Reproductive Health at the University of Virginia in 1990 and has worked in the field of reproductive biology since 1970 and in cancer biology since 1995. He is the key inventor on the patent applications related to SAS1B. Dr. Herr’s lab has been active in invention having identified or named more than 35 genes in the human genome (e.g., EPAD, CABYR, ACRV1, TSSK, ESP), and has applied for patents on their use as diagnostic or therapeutic targets.

Dr. Herr has a strong interest in technology commercialization and entrepreneurship, founding two previous biotechnology companies: Humagen, an IVF pipette company now a part of Origio, and ContraVac [d.b.a. SpermCheck], developer of the home sperm test SpermCheck Fertility sold nationwide in Walgreens stores. Dr. Herr has served on the Board of Directors of the University of Virginia Licensing & Ventures Group for 15 years.

Kimberly L. Blackwell, M.D.

Kimberly L. Blackwell is Professor of Medicine and Assistant Professor of Radiation Oncology at Duke University Medical Center. Since 2010, she has served as the director of the Breast Cancer Program in the Duke Cancer Institute, overseeing all basic and translational research programs involving breast cancer patients. Blackwell serves on the national Scientific Advisory Board of the Susan G. Komen Foundation.

One of the nation’s leading breast cancer researchers, Blackwell has played a major role in developing therapies that represent revolutionary non-chemotherapy based approaches for treating breast cancer. Her work on promising new therapies that selectively target breast tumor cells led to her inclusion on TIME magazine’s 2013 list of the 100 most influential people in the world.

Blackwell has authored or co-authored more than 70 articles or book chapters. She has clinical and research interests in breast cancer angiogenesis, breast cancer in younger women, endocrine therapy, and targeted therapy for breast cancer and has served as the principal investigator or co-principal investigator of more than 50 clinical trials.

Among her honors, Blackwell is a recipient of the Young Investigator Award in breast cancer from the Duke University Specialized Program of Research Excellence; the Duke Cancer Center Malek Family Award for outstanding cancer investigation; and the Joseph Greenfield Award for Mentorship of Clinical Research. In 2015 she was recognized as a distinguished Caskey Lecturer by the University of South Carolina, and was awarded the Distinguished Alumni award by Duke University.

Blackwell received her undergraduate degree in bioethics at Duke University and her medical degree at Mayo Clinic Medical School. She completed an internal medicine internship and residency and a hematology-oncology fellowship at Duke University Medical School, where she joined the faculty in 2000.

Jill Carroll, M.S.

Jill joined SR One in 2011 with a background in biotech partnering and commercial development. Prior to SR One, Jill was responsible for Corporate Development at Dynavax Technologies, where she was involved in multiple pharma partnering deals as well as substantial private and public financings. Previously, Jill was a consultant specializing in health care at Clearview Projects and Mercer Management Consulting.

Jill received her BS in Chemistry from Duke University, and her MS in Biochemistry, Cellular and Molecular Biology from Johns Hopkins University. Jill is a member of the Board of Directors of Vasculox and is involved with SR One’s investments in Progyny, Principia and eFFECTOR.

Gail McIntyre, Ph.D.

Gail McIntyre is the Vice President of Development for Meryx and oversees the drug development activities from lead optimization through to the submission of New Drug Application (NDA). Dr. McIntyre is board certified in clinical pathology (hematology and clinical chemistry) and toxicology. She is a member of the American College of Toxicology, the American College of Clinical Pharmacology, the American Society of Clinical Pathologists, the Drug Information Association and the American Association for the Advancement of Science.

Dr. McIntyre has more than 20 years of experience in the drug discovery and development industry. Her experience covers multiple therapeutic areas including oncology, infectious diseases, central nervous system and metabolic/endocrine as well as various therapies including small drugs, vaccines, immunomodulators, antibodies, immunoconjugates and peptide mimetics. Dr. McIntyre has prepared more than 30 regulatory submissions and ushered compounds through the lead optimization phase to early drug development and through to a new drug application (NDA). She was with PPD for 12 years and served as head of the company's compound partnering business for seven years before spinning out with Furiex in 2010.

Dr. McIntyre earned a bachelor's degree in biology from Merrimack College. Both her master's degree and doctorate in Biochemistry and Biophysics are from the University of North Carolina at Chapel Hill.